Oncolytics Biotech
ONCY
42 hedge funds and large institutions have $916K invested in Oncolytics Biotech in 2022 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 9 reducing their positions, and 6 closing their positions.
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
2% more funds holding
Funds holding: 41 → 42 (+1)
0.38% more ownership
Funds ownership: 1.28% → 1.66% (+0.38%)
17% less capital invested
Capital invested by funds: $1.11M → $916K (-$193K)
44% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ARC
Advisor Resource Council
Dallas,
Texas
|
+$122K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$86.5K |
| 3 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$43K |
| 4 |
Morgan Stanley
New York
|
+$39.6K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$24.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NDSI
Newman Dignan & Sheerar Inc
Providence,
Rhode Island
|
-$20K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$18K |
| 3 |
Two Sigma Advisers
New York
|
-$16.1K |
| 4 |
Renaissance Technologies
New York
|
-$14K |
| 5 |
Fifth Third Bancorp
Cincinnati,
Ohio
|
-$12.2K |
ONCY Hedge Fund Activity: Q2 2022 in Review
42 of the 5,960 institutional investors tracked by Wall St. Rank reported a position in Oncolytics Biotech (ONCY) for Q2 2022, worth a combined $916K — down 17% from $1.11M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ONCY positions and 6 closed out — a net gain of 1 holder — while 5 added to existing stakes and 9 trimmed.
The largest buyer was Advisor Resource Council, opening a new position worth an estimated $122K. The largest seller was Newman Dignan & Sheerar Inc, exiting entirely with an estimated $20K sold.
- 42 institutional investors held Oncolytics Biotech (ONCY) as of Q2 2022, up from 41 in Q1 2022.
- Funds reported $916K of Oncolytics Biotech stock for Q2 2022, down 17% quarter-over-quarter.
- 7 funds opened new Oncolytics Biotech positions in Q2 2022 and 6 closed out, a net change of +1 holder.
- The largest Oncolytics Biotech buyer in Q2 2022 was Advisor Resource Council, an estimated $122K added.
- The largest Oncolytics Biotech seller in Q2 2022 was Newman Dignan & Sheerar Inc, an estimated $20K sold.
Based on aggregated 13F filings for Q2 2022.